Recovery of pure red-cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietin

Internal Medicine Journal

Volumn 33, Issue 9-10, 2003, Pages 468-471

  Panchapakesan, U ^a,b   Austin, S K ^a   Shafransky, A ^a   Lawrence, J A ^a   Savdie, E ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Antierythropoietin antibodies; End stage renal failure; Pure red cell aplasia; Recombinant human erythropoietin

Indexed keywords

ANTIBODY; CYCLOSPORIN; DEFEROXAMINE; IRON; PREDNISONE; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANAMNESIS; ARTICLE; BLOOD TRANSFUSION; BONE MARROW EXAMINATION; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; CONVALESCENCE; DIAGNOSTIC ACCURACY; DISEASE COURSE; DOSE RESPONSE; DRUG WITHDRAWAL; ERYTHROPOIESIS; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOPRECIPITATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IRON THERAPY; KIDNEY FAILURE; LABORATORY TEST; MALE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; TREATMENT OUTCOME;

AUTOANTIBODIES; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RED-CELL APLASIA, PURE;

EID: 0142042387     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-5994.2003.00448.x     Document Type: Article

References (13)

1. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-75.
2. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252: 5558-64.
3. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A et al. Isolation and characterization of genomic cDNA clones of human erythropoietin. Nature 1985; 313: 806-10.
4. Faulds D, Sorkin EM. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. Drugs 1989; 38: 863-99.
5. Sasaki H, Bothner B, Dell A, Fukuda M. Carbohydrate structure of erythropoietin expressed in chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem 1987; 262: 12059-76.
6. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with Epoetin alfa in dialysis patients, J Am Soc Nephrol 1999; 10: 2392-5.
7. Casadevall N. Cellular mechanism of resistance to erythropoietin. Nephrol Dial Transplant 1995; 10: 27-30.
8. Peces R, de la Torre M, Alcazar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 1996; 335: 523-4.
9. Prabhakar S, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red-cell aplasia. Clin Nephrol 1997; 47: 331-5.
10. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996; 334: 630-3.
11. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346: 1584-6.
12. Casadevall N, Mayeux P. Pure red-cell aplasia and recombinant eryhopoietin. N Engl J Med 2002; 346: 1585.
13. Linardarki GD, Boki KA, Fertakis A, Tzioufas AG. Pure red-cell aplasia as presentation of systemic lupus erythematosus: antibodies to erythropoietin. Scand J Rheumatol 1999; 28: 189-91.